Titan Pharmaceuticals (NSDQ:TTNP) and Opiant Pharmaceuticals (NSDQ:OPNT) announced this week that the companies are partnering to develop a subcutaneous implant to deliver an opioid antagonist. The pair said they plan to conduct a feasibility assessment of such an implant using Titan’s ProNeura sustained release technology. The goal of their collaboration is to devise a way to […]
Implants
FDA deals setback to Intarcia for diabetes implant
Privately-held biopharma Intarcia Therapeutics revealed today that the FDA rejected its exenatide implant, ITCA 650, designed to treat Type II diabetes. The company said that it doesn’t think it will need to conduct new pivotal trials in order to address the concerns brought about by the FDA’s complete response letter. Intarcia hinted that the reason behind the […]
Intersect ENT touts meta-analysis of steroid-releasing sinus implant
Intersect ENT (NSDQ:XENT) touted data today from a meta-analysis of two studies assessing the safety and efficacy of its investigational steroid-releasing sinus implant, Sinuva. The studies evaluated Sinuva in patients with recurrent and medically refractory nasal polyps. The meta-analysis, which was presented at the American Rhinologic Society’s annual meeting, included data from the Resolve and Resolve […]
Federal judge dismisses faulty birth control suit against Merck
A Maine federal judge tossed out a woman’s lawsuit against Merck (NYSE:MRK), after she claimed that the company’s Nexplanon birth control implant allegedly failed to keep her from becoming pregnant. Kayla Doherty filed the suit in April 2015, seeking damages related to the costs of raising a child as a single mother and costs related to […]
Titan wins FDA nod to study Parkinson’s implant
Titan Pharmaceuticals (NSDQ:TTNP) said today that the FDA cleared the investigational new drug application for its ropinirole implant designed to treat the symptoms of Parkinson’s disease. The Phase I/II trial, which is slated to enroll 20 patients with idiopathic Parkinson’s disease, will transition patients taking oral ropinirole to Titan’s ropinirole implant for three months of treatment, […]
Titan Pharmaceuticals misses estimates in Q2
Shares in Titan Pharmaceuticals (NSDQ:TTNP) fell yesterday after the pharmaceutical company missed expectations on Wall Street with its second quarter results. The San Francisco, Calif.-based company posted a net loss of -$3.5 million on sales of $77,000 for the 3 months ended June 30. In the same period last year, Titan posted profits of $11.9 million […]
Endo swings to Q2 loss on $775m pelvic mesh set-aside
Endo International (NSDQ:ENDP) posted a net loss in the second quarter of this year, citing charges like the $775 million it has set aside to resolve 22,000 remaining lawsuits relating to the company’s vaginal-mesh implants. The generic drugmaker faced other setbacks this quarter, including the FDA asking that Endo pull its painkiller, Opana ER, from the […]
Intersect ENT tops EPS, sales estimates in Q2
Shares in Intersect ENT (NSDQ:XENT) surged today after the drug-device company beat expectations on Wall Street with its second quarter results. The Menlo Park, Calif.-based company posted a loss of -$2.3 million on sales of $24 million for the 3 months ended June 30, for bottom-line growth of 62% on sales growth of 24% compared […]
Titan Pharmaceuticals lands $10m debt facility
Titan Pharmaceuticals (NSDQ:TTNP) said last week that it inked a $10 million venture loan and security deal with Horizon Technology Finance Corp. The first $7 million tranche was triggered after the groups inked a deal, Titan reported, and a second option of $3 million is available to the California-based company until March 31, 2018, contingent upon […]
Medtech stories we missed this week: July 28, 2017
From Accenture’s AI-powered app to help the visually impaired to Rayovac getting clearance from Health Canada, here are seven medtech stories we missed this week but still thought were worth mentioning. 1. Accenture touts AI-powered app for visually impaired Accenture announced in a July 28 press release that it has developed an artificial intelligence–powered way to […]
